Sermorelin – Kodiac biolabs

Plain-language summaryIntrigue 60 / 100

Sermorelin is the first 29 amino acids of growth hormone releasing hormone (the active portion). It triggers natural pulsatile growth hormone release from the pituitary. Approved historically for pediatric growth hormone deficiency before being discontinued in 2008. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

38/100

Historically important GHRH fragment now superseded by longer-acting analogs with better pharmacokinetics

Sermorelin is the granddaddy of the GHRH peptide class. The 29-amino-acid N-terminal fragment of human GHRH, it retains full GHRHR agonist activity and was FDA-approved under the trade name Geref for pediatric GH deficiency before the brand was discontinued in 2008 for commercial reasons, not safety or efficacy ones. The mechanism is about as well-defined as it gets: GHRHR activation at the anterior pituitary, triggering pulsatile GH secretion. That signal has been observed and replicated in humans across multiple clinical programs, which is about the nicest thing we can say about the evidence base here.

Here’s the thing though: sermorelin is, by almost every research metric, the weakest member of the GHRH analog family available today. Its plasma half-life runs 11 to 12 minutes subcutaneously. CJC-1295 without DAC gives you a comparable pharmacological profile with a meaningfully longer active window; CJC-1295 with the drug affinity complex stretches GH stimulation across days by binding to albumin. Tesamorelin, the full GHRH(1-44) fragment stabilized for pharmaceutical use, earned FDA approval for HIV-associated lipodystrophy and carries a cleaner modern regulatory track record. Any of these outcompete sermorelin on pharmacokinetics or clinical validation, often both. For most research programs focused on the GH axis, sermorelin isnt the default choice anymore and hasnt been for some time.

The combination data with GHRPs is the most defensible current angle. Synergistic GH release when sermorelin is co-administered with ipamorelin or GHRP-2 has been documented and is mechanistically sensible: you’re hitting both GHRHR and the ghrelin receptor simultaneously, producing a larger and more sustained GH pulse than either agent alone. Some labs and compounding setups favor sermorelin specifically because of this established synergy literature. We think that’s a reasonable use case, but the same synergy is achievable with CJC-1295 and superior pharmacokinetics to boot.

Evidence quality is genuinely the bright spot. Multiple replicated clinical trials, a real regulatory history, and decades of preclinical mechanistic work give sermorelin a credibility that compounds like Epitalon or TB-500 will never match. The translational signal for GH deficiency is unambiguous. But research-merit scoring isnt about how much we trust something works for its approved indication; it’s about whether this is a compelling target right now. On that question, sermorelin lands squarely in established-mature territory: historically important, still serviceable as a GHRHR probe for acute GH axis work, but not where the interesting mechanistic questions are being asked in 2025 and 2026. The field has produced better tools for the same job.

Novelty: 22
Mechanism promise: 35
In-category differentiation: 22
Evidence quality: 62
Translational signal: 60
Research bench value: 38

Rationale Sermorelin’s FDA history (Geref, pediatric GH deficiency) and replicated clinical evidence are genuine assets, but the 11-12 minute plasma half-life and wide availability of CJC-1295 variants leave it in the superseded tier of GHRH analogs; low novelty and differentiation scores drag the overall into the established-mature range.

GHRH 1-29 analog

A 29-amino-acid synthetic fragment of GHRH (residues 1-29) used for growth hormone deficiency diagnosis and treatment.

Abstract

Sermorelin (GRF 1-29; CAS 86168-78-7; molecular weight 3357.93) is a synthetic peptide consisting of the first 29 amino acids of human growth hormone releasing hormone (GHRH). The 1-29 fragment retains essentially all the GH-stimulating activity of full-length GHRH (44 residues) and was the basis for the FDA approval (under the trade name Geref) for GH deficiency in children. The brand-name product was discontinued in 2008 for commercial reasons; sermorelin is now compounded for clinical use in some jurisdictions and sold as a research chemical. The compound is administered subcutaneously and stimulates pituitary GH release through GHRH receptor activation, distinct from the ghrelin receptor agonism of GHRPs. Combination of sermorelin with a GHRP (ipamorelin, GHRP-2) produces synergistic GH release. Pharmacokinetics: plasma half-life 11 to 12 minutes; subcutaneous bioavailability good. Doses for GH deficiency are 0.3 mcg/kg subcutaneously once daily at bedtime.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-079Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.